Giovanni Di Perri

AIDS-Related Kaposi’s Sarcoma: Evaluation of Potential New Prognostic Factors and Assessment of the AIDS Clinical Trial Group Staging System in the Haart Era—the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naïve From Antiretrovirals

Guglielmo Nasti, Renato Talamini, Andrea Antinori et al. · Journal of Clinical Oncology · 2003 · 172 citations

Medicine, Infectious Diseases, Oncology +16

Transbronchial Biopsy in the Diagnosis of Pulmonary Infiltrates in Immunocompromised Patients

Angelo Cazzadori, Giovanni Di Perri, Giuseppe Todeschini et al. · CHEST Journal · 1995 · 118 citations

Medicine, Immunology, Pathology +16

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

Moti Ramgopal, Antonella Castagna, Charles Cazanave et al. · The Lancet HIV · 2023 · 115 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome–related Kaposi sarcoma

Guglielmo Nasti, Ferdinando Martellotta, Massimiliano Berretta et al. · Cancer · 2003 · 100 citations · Full text

Life Sciences, Immunology, Infectious Diseases +16

Parasitologic Findings in Percutaneous Drainage of Human Hydatid Liver Cysts

Carlo Fìlice, Giovanni Di Perri, M. Strosselli et al. · The Journal of Infectious Diseases · 1990 · 41 citations

Veterinary Medicine, Infectious Diseases, Pathology +17